Most treatment-related side effects are rapidly reversible1-3
Like most immunotherapies, mRCC or mM patients are likely to experience side effects with treatment. With Proleukin1-3:
Treatment-related side effects can be managed at specialized IL-2 Treatment Centers.
Long-term sequelae associated with Proleukin are extremely rare and may include myocardial infarction, bowel perforation, and gangrene.3
Most treatment-related side effects are manageable, rapidly reversible, and improve within 2 to 3 days of stopping therapy.1-3
Proleukin administration has been associated with capillary leak syndrome.1 Please see full Prescribing Information and complete Boxed Warning.
Your patients will be well cared for at specialized IL-2 Treatment Centers
Throughout treatment, a specially trained team of healthcare professionals will:
- Monitor your patients 24/7 to anticipate treatment-related side effects and to provide rapid response1,3
- Do everything they can to keep your patients as comfortable as possible throughout treatment
- Withhold doses of Proleukin at any stage when needed to assist with adverse event management1

Some specialized IL-2 Treatment Centers have over 20 years of real-world clinical experience administering Proleukin and have provided effective strategies to manage side effects.1,4
Common Adverse Events Reported in ≥ 10% of Patients (Any Grade, n = 525)1


aCardiovascular disorder: fluctuations in blood pressure, asymptomatic ECG changes, CHF.
bLung disorder: physical findings associated with pulmonary congestion, rales, rhonchi.
cRespiratory disorder: ARDS, CXR infiltrates, unspecified pulmonary changes.
Life-Threatening (Grade 4) Adverse Events Reported in ≥ 1% of Patients (n = 525)1


dCardiovascular disorder: fluctuations in blood pressure.
eCoagulation disorder: intravascular coagulopathy.
fRespiratory disorder: ARDS, respiratory failure, intubation.
•
|
Explaining that side effects are common with most immunotherapies, including Proleukin1
|
•
|
Reminding patients that everyone is unique and will respond to side effects differently1
|
•
|
Reassuring patients that they will be monitored 24/7 by a multidisciplinary team trained in administering Proleukin and managing side effects1-3
|
•
|
Explaining to patients that most treatment-related side effects improve 2 to 3 days after stopping treatment with Proleukin1-3
|

Providing hope is possible with Proleukin.
Objective response was seen in 16% of mM patients (6% complete and 10% partial responders) and in 15% of mRCC patients (7% complete and 8% partial responders).1
References: 1. Proleukin [package insert]. Yardley, PA: Clinigen, Inc; 2019. 2. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688-696. 3. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105-2116. 4. Dutcher JP, Schwartzentruber DJ, Kaufman HL, et al. High dose interleukin-2 (aldesleukin)—expert consensus on best management practices—2014. J Immunother Cancer. 2014;2(1):26. 5. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6(suppl 1):S55-S57. 6. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6(suppl 1):S11-S14.